胰腺癌的表观遗传学靶向治疗。

Epigenetic targeting in pancreatic cancer.

机构信息

Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands; Department of Urology 267, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands.

Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands.

出版信息

Cancer Treat Rev. 2014 Jun;40(5):656-64. doi: 10.1016/j.ctrv.2013.12.002. Epub 2014 Jan 3.

DOI:10.1016/j.ctrv.2013.12.002

PMID:24433955

Abstract

The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years it became evident that deregulation of epigenetic mechanisms plays an important role in pancreatic carcinogenesis. This review focuses on the exploitation of drugs that alter histone modifications, DNA methylation and microRNA expression as options for the treatment of pancreatic cancer.

摘要

胰腺癌患者的预后非常差，5 年生存率不足 6%。因此，胰腺癌迫切需要新的治疗选择。过去几年，表观遗传机制失调在胰腺癌发生中起着重要作用已变得显而易见。本文综述了改变组蛋白修饰、DNA 甲基化和 microRNA 表达的药物作为治疗胰腺癌的选择。